Clinical Trial Update: BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for the BATTLE program evaluating Tarceva and Targretin in patients with advanced non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Targretin (bexarotene)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-01-21